INTRODUCTION {#s1}
============

Medullary thyroid cancer (MTC) accounts for 5%--8% of all thyroid cancers, but unlike the majority of thyroid malignancies that are derived from the follicular cells of the gland, MTC represents the malignant transformation of the calcitonin-producing parafollicular C cells ([@KASAIANMCS000729C6]). Although 25% of MTCs are hereditary and categorized, depending on the presence of other endocrinopathies, as either familial MTC or multiple endocrine neoplasia type 2 (MEN2) syndrome, the majority of diagnosed cases are sporadic ([@KASAIANMCS000729C11]). Germline activating point mutations of *rearranged during transfection* (*RET*) are the known causative alterations in \>95% of hereditary MTCs; somatic mutations of this oncogene are also found in 50% of sporadic MTCs ([@KASAIANMCS000729C6]). Activating somatic mutations of *RAS* genes are found in subpopulations of *RET* mutation-negative sporadic MTCs ([@KASAIANMCS000729C22]; [@KASAIANMCS000729C2]). Although the majority of studies of MTC have not identified the BRAF V600E activating mutation, commonly implicated in papillary thyroid cancer ([@KASAIANMCS000729C22]; [@KASAIANMCS000729C2]; [@KASAIANMCS000729C1]), a Korean study and a Greek study have reported the presence of this well-characterized driver alteration in MTC patients ([@KASAIANMCS000729C12]; [@KASAIANMCS000729C8]). This may be the result of technical variations such as the chosen validation techniques or differences in tissue handling and processing or may be indicative of population-specific cancer drivers.

Five- and 10-yr survival rates in patients diagnosed with MTC are reported at 86% and 78%, respectively, and these plummet to 25% and 10% after discovery of distant metastasis ([@KASAIANMCS000729C24]; [@KASAIANMCS000729C11]), rendering MTC as more aggressive than the commonly diagnosed follicular-derived thyroid malignancies. MTC is resistant to chemotherapy and radiation therapy and hence complete surgical removal of the thyroid gland is the primary and the most promising curative treatment for localized disease ([@KASAIANMCS000729C11]). The majority of mortality that occurs due to MTC is, however, due to local and distant metastasis when the primary clinical management of the disease is palliation ([@KASAIANMCS000729C24]). The effectiveness of external beam radiation therapy (EBRT) in the treatment of MTC has been controversial; a study evaluating 66 MTC patients identified in the Surveillance, Epidemiology, and End Results database (SEER; seer.cancer.gov) that were treated with EBRT found that after controlling for known prognostic factors, the overall survival benefit attributed to EBRT in node-positive patients by univariate analysis was lost ([@KASAIANMCS000729C21]). Radiation therapy is believed to be effective in preventing local disease recurrence only in patients with high-risk features such as the presence of residual disease, nodal positivity, and extranodal cancer extension ([@KASAIANMCS000729C3]; [@KASAIANMCS000729C10]; [@KASAIANMCS000729C4]). Hence, the American Thyroid Association guidelines for the management of medullary thyroid cancer recommend the use of postoperative EBRT only for those patients at high risk of local disease recurrence to achieve local control ([@KASAIANMCS000729C29]). The Food and Drug Administration has approved the use of the kinase inhibitors vandetanib and cabozantinib for the treatment of advanced medullary thyroid cancer. Vandetanib operates by blocking RET, VEGFRs (vascular endothelial growth factor receptors), and EGFR (epidermal growth factor receptor) ([@KASAIANMCS000729C28]), whereas cabozantinib inhibits the activity of MET (mesenchymal epithelial transition), VEGFR, and RET ([@KASAIANMCS000729C9]). Although these therapeutics resulted in statistically significant progression-free survival, they do not lead to measurable responses in all patients presenting with advanced and metastatic disease. Additionally, most individuals on treatment who initially respond will eventually progress and die from MTC; thus, there is still a great need for more effective treatments. Here, we provide the genomic analysis of two MTC tumors and report, for the first time, the presence of a putative activating *BRAF* fusion in one of the tumors.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

Patient A is a male of East Indian descent who in 2010 at the age of 33 presented with a left lateral neck mass that by biopsy was diagnosed as an MTC. His serum calcitonin level was 1562 ng/L and his CEA (carcinoembryonic antigen) was 440 µg/L at presentation; he was otherwise asymptomatic. He had no personal or family history of thyroid cancer or other endocrine tumors. He also had no personal history of head and neck radiation exposure. Biochemical screening for parathyroid and adrenal tumors was negative. He underwent a total thyroidectomy, central neck dissection, and selective left lateral neck dissection. At the time of surgery, he was found to have a locally advanced cancer with extensive invasion of his larynx, trachea, esophagus, and the left recurrent laryngeal nerve, which required sacrificing. There were two MTC foci measuring 0.9 and 1.2 cm present in the thyroid and both were positive for calcitonin and CEA immunohistochemistry. Four of 12 lymph nodes had evidence of metastatic MTC and there was no evidence of extrathyroidal cancer extension. Final staging of his cancer was T4N1bM0. He was treated postoperatively with EBRT. He was followed up by his endocrinologist and radiation oncologist every 4--6 mo and underwent laboratory (calcitonin and CEA) and imaging (CT \[computed tomography\] of neck, chest, and abdomen) surveillance. During follow-up, he never developed any evidence of structural recurrence. Four years and 11 mo after his operation he was alive and in good health with a calcitonin that was 13 ng/L and a CEA that was 3.1 µg/L, with no gross clinical or imaging evidence of disease.

Patient B, a woman of Scottish/Irish/German descent, was diagnosed at the age of 31 in 2012. She presented with what was believed to be postpartum thyroiditis, and an ultrasound revealed a left 4.7-cm thyroid mass. She had no ultrasound evidence of lateral neck disease. A biopsy of the mass diagnosed MTC. Her serum calcitonin level was 289 ng/L and her CEA was 120 µg/L at presentation. She had no personal history of cancer or head and neck radiation exposure. She had no family history of thyroid cancer or endocrine tumors, although she had a maternal grandmother who had a history of breast cancer that was diagnosed at 48 yr of age. Biochemical screening for parathyroid and adrenal tumors was negative. She underwent a total thyroidectomy and central neck dissection. The MTC measured 2.5 cm, was positive for calcitonin and CEA immunohistochemistry, and had evidence of capsular invasion. There was no evidence of metastases in the eight lymph nodes that were removed from the central neck. Final staging for her cancer was T2N0M0. Postoperatively she was followed up by her endocrinologist every 4--6 mo and underwent laboratory (calcitonin and CEA) and imaging (CT of neck, chest, and abdomen) surveillance. During follow-up, she never developed any evidence of structural recurrence. Three years and 5 mo after her operation, she was alive and in good health with a calcitonin level that was \<5 ng/L and a CEA that was \<0.5 µg/L, with no gross clinical or imaging evidence of disease.

Genomic Analysis {#s2b}
----------------

Whole-genome sequencing of both tumors and matched normal tissues and whole-transcriptome sequencing of both tumors were performed. Genomic profiling of the MTC procured from Patient A at the time of thyroidectomy revealed a very mutationally quiet genome with only seven single-nucleotide somatic variants ([Table 1](#KASAIANMCS000729TB1){ref-type="table"}) and no small insertions and deletions, copy-number changes, or large-scale structural alterations. The only evident and known driver mutation in this patient\'s MTC was the activating p.Q61L KRAS mutation that has previously been described in MTCs ([@KASAIANMCS000729C22]; [@KASAIANMCS000729C2]; [@KASAIANMCS000729C1]). The genome of the MTC procured from Patient B harbored 18 single-nucleotide somatic variants ([Table 2](#KASAIANMCS000729TB2){ref-type="table"}). Unlike Patient A\'s MTC, this genome demonstrated regions of copy-number variation with loss of one copy, and as a result loss of heterozygosity (LOH) of Chromosomes 1p, 4q, 7, 18, 21, and 22 ([Fig. 1](#KASAIANMCS000729F1){ref-type="fig"}). We also identified three gene fusions, all resulting from local duplication events ([Table 3](#KASAIANMCS000729TB3){ref-type="table"}). A noteworthy fusion was that of *PARP12* and *BRAF* genes. A duplication event on Chromosome 7 led to the fusion of these two genes, producing a putative fusion oncogene with an intact kinase domain; this fusion was expressed and identified in the transcriptome data set. Neither of the MTCs had germline or somatic *RET* mutations. Medullary thyroid cancers show a low mutation rate and in the majority of cases carry only one known driver mutation consistent with an oncogenic addiction profile ([@KASAIANMCS000729C1]). Previous studies using low-resolution techniques, such as array comparative genomic hybridization, have also alluded to the rare occurrence of copy-number changes in MTCs and that this cancer can arise without any chromosomal changes or *RET* activating mutations ([@KASAIANMCS000729C11]) supporting our observations on the whole-genome scale.

![B-allele frequencies (frequency of the alternate allele) of common single-nucleotide polymorphisms (SNPs) in the tumors of Patient A (*top*) and Patient B (*bottom*) are plotted for each chromosome. Although no regions of loss of heterozygosity (LOH) were observed in Patient A, the second patient demonstrated regions of LOH in Chromosomes 1p, 4q, 7, 18, 21, and 22.](KasaianMCS000729_F1){#KASAIANMCS000729F1}

###### 

Small somatic variants identified in the tumor genome of Patient A

  Gene        Chromosome   HGVS DNA reference   HGVS protein reference   Variant type   Predicted effect     dbSNP ID    Genotype       Read depth   Allele frequency
  ----------- ------------ -------------------- ------------------------ -------------- ------------------ ------------- -------------- ------------ ------------------
  *BIRC6*     2            c.10592C\>A          p.S3531Y                 Substitution   Missense                ---      Heterozygous   41           0.1
  *RUNDC3B*   7            c.654G\>C            p.E218D                  Substitution   Missense                ---      Heterozygous   39           0.18
  *SCGB1C1*   11           c.13C\>T             p.R5C                    Substitution   Missense             rs7951297   Heterozygous   40           0.175
  *NELL1*     11           c.1942A\>C           p.S648R                  Substitution   Missense                ---      Heterozygous   29           0.14
  *KRAS*      12           c.182A\>T            p.Q61L                   Substitution   Missense            rs121913240  Heterozygous   36           0.22
  *COPS2*     15           c.605T\>C            p.D202G                  Substitution   Missense                ---      Heterozygous   35           0.14
  *MT-ATP6*   MT           c.577T\>C            p.F193L                  Substitution   Missense                ---      Heterozygous   9787         0.04

HGVS, Human Genome Variation Society; dbSNP, Database for Short Genetic Variations.

###### 

Small somatic variants identified in the tumor genome of Patient B

  Gene       Chromosome   HGVS DNA reference   HGVS protein reference   Variant type   Predicted effect      dbSNP ID    Genotype       Read depth   Allele frequency
  ---------- ------------ -------------------- ------------------------ -------------- ------------------- ------------- -------------- ------------ ------------------
  *DUSP10*   1            c.392G\>A            p.S131N                  Substitution   Missense                 ---      Heterozygous   25           0.48
  *STAG1*    3            c.863T\>G            p.M288R                  Substitution   Missense                 ---      Heterozygous   33           0.58
  *KIF9*     3            c.1036A\>C           p.T346P                  Substitution   Missense                 ---      Heterozygous   25           0.48
  *MAP3K4*   6            c.3720A\>G           p.I1240M                 Substitution   Missense                 ---      Heterozygous   33           0.42
  *NAMPT*    7            c.1456C\>G           p.L486V                  Substitution   Missense                 ---      Homozygous     11           1
  *RGS3*     9            c.527T\>C            p.V176A                  Substitution   Missense                 ---      Heterozygous   16           0.69
  *MAMDC4*   9            c.1844G\>A           p.R615Q                  Substitution   Missense                 ---      Heterozygous   22           0.45
  *UBE3B*    12           c.560C\>G            p.P187R                  Substitution   Missense                 ---      Heterozygous   27           0.48
  *NACA*     12           c.3568T\>C           p.S1190P                 Substitution   Missense              rs2958150   Heterozygous   14           0.29
  *PSPC1*    13           c.1474A\>G           p.M492V                  Substitution   Missense             rs75085951   Heterozygous   36           0.16
  *MDP1*     14           c.377G\>A            p.R126Q                  Substitution   Missense                 ---      Heterozygous   22           0.5
  *CDRT1*    17           c.68T\>A             p.I23N                   Substitution   Missense             rs201445711  Heterozygous   28           0.18
  *LOXHD1*   18           c.5417T\>A           p.H1806L                 Substitution   Missense                 ---      Heterozygous   11           0.18
  *PLK5*     19           ---                  ---                      Substitution   Splice site donor    rs10853954   Heterozygous   27           0.44
  *PSG5*     19           c.955G\>A            p.E319K                  Substitution   Missense             rs17406362   Heterozygous   37           0.51
  *PES1*     22           c.737C\>G            p.T246S                  Substitution   Missense                 ---      Heterozygous   9            0.22
  *MT-ND1*   MT           c.106G\>A            p.G36S                   Substitution   Missense                 ---      Heterozygous   2722         0.13
  *MTM1*     X            c.700G\>A            p.H234Y                  Substitution   Missense                 ---      Heterozygous   33           0.45

HGVS, Human Genome Variation Society; dbSNP, Database for Short Genetic Variations.

###### 

Detected gene fusions in the tumor of Patient B

  Gene         Genomic breakpoint coordinate   Gene        Genomic breakpoint coordinate  Translated
  ------------ ------------------------------- ---------- ------------------------------- ------------
  *BRAF*       Chr7:140482184                  *PARP12*           Chr7:139728271          Yes
  *TMEM132D*   Chr12:129579191                 *RIMBP2*           Chr12:130930789         Yes
  *DNAJC17*    Chr15:41083978                  *RYR3*             Chr15:34113093          No

DISCUSSION {#s3}
==========

Surgery is the only curative form of treatment for patients presenting with MTC ([@KASAIANMCS000729C24]). However, persistent disease is observed in 70% of sporadic cases, which are generally resistant to chemotherapy and radiation ([@KASAIANMCS000729C24]). Targeted therapies may thus be the only promising option for the treatment of advanced and refractory MTCs. Half of sporadic MTCs harbor *RET* activating point mutations ([@KASAIANMCS000729C1]), and the multikinase inhibitors vandetanib and cabozantinib, which act by blocking the kinase activity of several proteins including RET, are approved for use in the treatment of MTC. These therapies, however, do not lead to measurable responses in all patients with advanced and metastatic disease; detailed analysis of MTC tumors on the genome scale may thus provide clues into yet undefined driver mutations.

In this report, we have described, to the best of our knowledge, the first whole-genome analysis of medullary thyroid carcinoma and the first MTC to harbor a putative oncogenic *BRAF* fusion. Both studied MTCs were considered sporadic disease that lacked somatic (or germline) *RET* alterations. Whole-genome sequence coverage of 30×--40× was produced in the current study ([Table 4](#KASAIANMCS000729TB4){ref-type="table"}). Although genome resequencing experiments can rely on an average depth of 35× ([@KASAIANMCS000729C27]), sample and tumor heterogeneity in addition to aneuploid genomes that are observed in almost all cancer specimens require a higher depth of sequence coverage for identifying all relevant somatic mutations. Although the current data sets provided reliable fusion and copy-number profiles at the base-level resolution, they may not have been as robust in describing single-nucleotide variants (SNVs) and small insertions and deletions. Low coverage in the tumor or the matched normal tissue may have resulted in false-negative or false-positive somatic calls, respectively, whereas the studied data sets did not have the power to detect subclonal events.

###### 

Coverage statistics for the sequence libraries

               Tumor genome coverage   Normal genome coverage   Number of tumor transcriptome reads
  ----------- ----------------------- ------------------------ -------------------------------------
  Patient A             38×             39× (normal tissue)                    149M
  Patient B             29×                 28× (blood)                        284M

M, million.

One patient had an activating *KRAS* mutation; the other lacked any *RAS* mutations but harbored a *BRAF* fusion ([Fig. 2](#KASAIANMCS000729F2){ref-type="fig"}). None of the approved targeted therapeutics for MTC shows activity against BRAF, and therefore profiling MTC patients for fusions or other alterations of *BRAF* may warrant the utilization of drugs such as sorafenib, vemurafenib, regorafinib, or dabrafenib for the treatment of MTC, contingent on functional validation of these putative oncogenic events. Several BRAF fusions have demonstrated insensitivity to ATP-competitive RAF inhibitors, whereas other in vitro studies showed sensitivity to MEK (mitogen-activated protein kinase kinase) inhibitor therapy; detailed biochemical and clinical characterization of the *BRAF* mutational spectrum is essential for tailored therapeutic intervention ([@KASAIANMCS000729C16]; [@KASAIANMCS000729C25]; [@KASAIANMCS000729C15]). A recent case report described an activating *RET* fusion in a sporadic MTC patient with no *RET* or *RAS* point mutations ([@KASAIANMCS000729C13]), and another the presence of *ALK* fusions in two MTC patients ([@KASAIANMCS000729C17]). These studies and our report of the *BRAF* fusion suggest a need for more comprehensive profiling of these tumors and the utilization of techniques capable of detecting large-scale structural events such as gene fusions.

![Duplication on Chromosome 7 resulted in an in-frame fusion of *PARP12* and *BRAF* genes in the MTC tumor of Patient B producing a putative fusion oncogene harboring *PARP12* exons 1--9 and *BRAF* exons 11--18. ORF, open reading frame; ZF, zinc finger; WWE, Trp-Trp-Glu.](KasaianMCS000729_F2){#KASAIANMCS000729F2}

Currently upon presentation and depending on the institutional practices, MTC patients may be tested for the presence of point mutations in *RET*, activation of which leads to the activation of downstream signaling pathways including RAS--RAF--ERK and PI3K--AKT pathways. Mutations of various members of the same signaling pathway can exert a similar effect on the phenotype, and thus *RET* mutation-negative MTCs may harbor alterations of other signaling proteins in these networks. Such pathway-level mutual exclusivity has been observed in papillary thyroid cancers where *RET* fusions, *BRAF*, and *RAS* activating mutations were not found together in any tumor; all, however, are members of the same signaling pathway ([@KASAIANMCS000729C5]). Cancer cases with no *RET* point mutations may harbor alterations such as oncogenic gene fusions of other members of its signaling pathways. More effective targeted treatment can thus be made possible through comprehensive mutational profiling of key signaling molecules in cancer pathways.

METHODS {#s4}
=======

DNA from the two flash-frozen MTC tumors and matched normal specimens were subjected to whole-genome sequencing; 100-bp paired-end sequence reads were generated on Illumina HiSeq2500 instruments following the manufacturer\'s protocol with minor variations. In addition, 75-bp paired-end transcriptome sequence reads were produced for the tumors ([Table 4](#KASAIANMCS000729TB4){ref-type="table"}).

Sequence reads from the whole-genome libraries were aligned to the human reference genome (build GRCh37) using the Burrows--Wheeler alignment (BWA) tool ([@KASAIANMCS000729C19]). The tumor\'s genomic sequence was compared with that of the patient\'s constitutive DNA to identify somatic alterations. Regions of copy-number variation and LOH were determined using hidden Markov model--based approaches HMMcopy and APOLLOH ([@KASAIANMCS000729C14]), respectively. De novo assembly and annotation of genomic data using ABySS and Trans-ABySS ([@KASAIANMCS000729C26]) were used to identify small insertions and deletions (indels) and large structural variants (SVs) including translocations, inversion, and duplications leading to gene fusions; identified SVs were verified using an orthogonal alignment--based detection tool, BreakDancer ([@KASAIANMCS000729C7]). Single-nucleotide variants and indels in the tumor/normal pair were identified using a probabilistic joint variant calling approach utilizing SAMtools and Strelka ([@KASAIANMCS000729C20]; [@KASAIANMCS000729C23]). Sequence reads from the transcriptome libraries were aligned to the human reference genome (build GRCh37) using TopHat ([@KASAIANMCS000729C18]) with Ensembl gene model annotation file on the -G parameter. The reference sequence and the corresponding annotation files were provided by Illumina\'s iGenome project and downloaded from the TopHat homepage (<http://ccb.jhu.edu/software/tophat/index.shtml>). Structural variants were identified using a de novo assembly-based approach using ABySS and Trans-ABySS ([@KASAIANMCS000729C26]) and the alignment-based SV detection tool MOJO (Minimum Overlap Junction Optimizer; <https://github.com/cband/MOJO>).
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======================
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